REG - Arix Bioscience Plc - Director/PDMR Shareholding
02/05/2023 16:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230502:nRSB1654Ya&default-theme=true
RNS Number : 1654Y Arix Bioscience Plc 02 May 2023
Arix Bioscience plc
("Company")
PDMR notifications & Director Shareholdings
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.
Arix Bioscience Plc has been notified of the following transactions relating
to the below named PDMRs and their respective interests in the ordinary share
capital of the Company ('Shares'):
Peregrine Moncreiffe, Non-Executive Director and Chairman of the Board
purchased 75,000 Ordinary shares of 0.001 pence each in the Company ("Shares")
on 27 April 2023 at a price of 102.5 pence per share and purchased a further
85,000 Shares in the Company on 28 April 2023 at a price of 104.8 pence per
share.
Debra Barker, Non-Executive Director and Senior Independent Director purchased
24,000 Shares in the Company on 27 April 2023 at a price of 103 pence per
share.
Robert Lyne, Chief Executive Officer purchased 24,330 Shares in the Company on
27 April 2023 at a price of 102.75 pence per share.
In a separate transaction, Robert Lyne exercised vested options over 203,764
shares ("Option Shares") on 27 April 2023 pursuant to a nil cost share award
granted on 30 June 2020. 96,107 of the Shares were sold on 27 April 2023 at a
sale price of 101.5 pence per share to satisfy the resultant income tax and
National Insurance liability.
The notification below, made in accordance with the requirements of UK Market
Abuse Regulation, provides further detail on the respective transactions.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Peregrine Moncreiffe
2 Reason for the notification
a) Position/status Non-Executive Director and Chair of the Board
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Arix Bioscience plc
b) LEI 213800OVT3AHQCXNIX43
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Arix Bioscience plc Ordinary shares of 0.001 pence each
Identification code GB00BD045071
b) Nature of the transaction Share purchase
c) Price(s) and volume(s) Price(s)£ Volume(s)
27 April 2023 1.025 75,000
28 April 2023 1.048 85,000
d) Aggregated information
- Aggregated volume 160,000
- Price £165,962.50
e) Date of the transaction 27 April
2023
28 April 2023
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Robert Lyne
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Arix Bioscience plc
b) LEI 213800OVT3AHQCXNIX43
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Arix Bioscience plc Ordinary shares of 0.001 pence each
Identification code GB00BD045071
b) Nature of the transaction Share Purchase
c) Price(s) and volume(s) Price(s)£ Volume(s)
£1.0275 24,330
d) Aggregated information
- Aggregated volume N/A (Single Transaction)
- Price £24,999.08
e) Date of the transaction 27 April 2023
f) Place of the transaction London Stock Exchange
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Robert Lyne
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Arix Bioscience plc
b) LEI 213800OVT3AHQCXNIX43
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Arix Bioscience plc Ordinary shares of 0.001 pence each
Identification code GB00BD045071
b) Nature of the transaction Vesting of awards under the Company's Executive Incentive Plan ("EIP") 2020
and sale of shares to cover associated tax liabilities
c) Price(s) and volume(s) Price(s)£ Volume(s)
1.) Acquisition £nil per share 203,764
2.) Disposal £1.015 96,107
d) Aggregated information
- Aggregated volume N/A (Single Transaction)
- Price £97,548.61
e) Date of the transaction 27 April 2023
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Debra Barker
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Arix Bioscience plc
b) LEI 213800OVT3AHQCXNIX43
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Arix Bioscience plc Ordinary shares of 0.001 pence each
Identification code GB00BD045071
b) Nature of the transaction Share purchase
c) Price(s) and volume(s) Price(s) £ Volume(s)
£1.03.00 24,000
d) Aggregated information
- Aggregated volume N/A (single transaction)
- Price £24,720.00
e) Date of the transaction 27 April
2023
f) Place of the transaction London Stock Exchange
Ends.
For further information please contact:
Kin Company Secretarial Limited, Company Secretary
+44 20 8819 6486
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHZLLFBXELEBBFRecent news on Arix Bioscience
See all newsREG - Stock Exch Notice Arix Bioscience Plc - Cancellation - Arix Bioscience plc
AnnouncementREG-Arix Bioscience PLC Scheme Effective
AnnouncementREG - Official List - Suspension - Arix Bioscience plc
AnnouncementREG-Arix Bioscience PLC Suspension of Trading in Shares
AnnouncementREG-Arix Bioscience PLC Transaction Update
Announcement